Shigella sonnei vaccine - GlaxoSmithKline

Drug Profile

Shigella sonnei vaccine - GlaxoSmithKline

Alternative Names: 1790GAHB vaccine

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline
  • Class Bacterial vaccines; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Shigella infections

Most Recent Events

  • 15 Feb 2016 GSK Vaccines Institute For Global Health plans a phase IIa trial for Shigella infections (Prevention, In volunteers) in Kenya (IM) (NCT02676895)
  • 02 Mar 2015 GlaxoSmithKline acquires Shigella sonnei vaccine from Novartis
  • 01 Mar 2014 Phase-I clinical trials in Shigella infections (in volunteers) in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top